Joining the global #OrangeTheWorld movement to end violence against women and girls. From November 25-December 10, we're part of the UN's UN Women worldwide campaign spanning 196 countries. Our Turku facility will glow orange alongside thousands of landmarks globally, adding our voice to millions united in creating a world free from violence. One global mission. One orange light of hope. http://ms.spr.ly/6042tnTCg #OrangeTheWorld #EndViolenceAgainstWomen #NoExcuse #UNWomen #Revvity
Revvity
Biotechnology Research
Waltham, Massachusetts 224,520 followers
Expanding the boundaries of human potential through science
About us
At Revvity, “impossible” is inspiration, and ""can't be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Learn more at www.revvity.com
- Website
-
http://www.revvity.com
External link for Revvity
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
- Founded
- 2023
Locations
-
Primary
Get directions
940 Winter St.
Waltham, Massachusetts 02451, US
Employees at Revvity
Updates
-
For over 60 years, newborn screening has saved lives. Now, next-generation sequencing (NGS) is taking it further, revealing rare, treatable conditions just days after birth. Powered by insight and collaboration, the future of newborn care is here. See how we’re redefining early life care. http://ms.spr.ly/6045tTXYV #ChallengeAccepted #NewbornScreening #Genomics #Revvity
-
-
What does it take to spark curiosity in the scientists and innovators of tomorrow? Commitment. Collaboration. And a shared belief in the power of opportunity. For the second year in a row, our Revvity team — joined by our Chief People Officer Magali Four — partnered with Science Club for Girls to help advance their mission of making STEM engaging, inclusive, and accessible for girls and gender-expansive youth. During the volunteer event, our colleagues assembled thousands of hands-on science materials, from components for a Space Station design activity to supplies for a gravity-focused experiment. These kits will soon make their way into classrooms, supporting curiosity-driven learning across the community. We’re honored to champion organizations like SCFG that are cultivating the next generation of thinkers, creators, and leaders. #STEMEducation #WomenInSTEM #ScienceClubForGirls #WeAreRevvity
-
-
Our eye-catching image for November shows A549 cells on a Semarion SemaCyte® microcarrier, stained with the PhenoVue™ Cell Painting JUMP kit and imaged on the Opera Phenix™ Plus HCS system. Watch our webinar to learn how this combination of technologies facilitates analysis of multiple cell lines in a single well. View now. http://ms.spr.ly/6043t3W6c
-
-
On World Diabetes Day, let’s amplify the message: T1D isn’t preventable yet—but its complications are. Early screening and autoantibody monitoring can help families act sooner. Together, we can change the future of diabetes. http://ms.spr.ly/6040tPypK #WorldDiabetesDay #T1DAwareness #ScreenEarly #RevvityOmics
-
Artificial intelligence is transforming the modern lab — but how can research leaders prepare their teams to integrate it effectively? In Lab Manager, Mary Donlan, PhD, from Revvity Signals, shares a strategic guide for research managers on adopting AI in the lab — from building readiness to ensuring successful implementation. Discover practical insights on how AI can accelerate data-driven discovery and collaboration: http://ms.spr.ly/6046tMSQj
-
Revvity reposted this
We’re excited to announce that we have entered into a definitive agreement for acquisition by Revvity Signals. Together, ACD/Labs and Revvity Signals will support entire scientific workflows—from discovery and development to scale-up and manufacturing— enabling scientists to interpret, manage, and act on complex data with greater speed and confidence. Learn more: https://lnkd.in/eZuCEncB
We’re excited to announce that Revvity has entered into a definitive agreement to acquire ACD/Labs, a global leader in analytical and chemical intelligence: http://ms.spr.ly/6041tzvHS This acquisition strengthens our #RevvitySignals portfolio, bridging the gap between analytical data and actionable insight across discovery, development, and manufacturing. Together, we’ll deliver unified, end-to-end solutions that accelerate innovation in pharma and material sciences. #ScientificSoftware #ACDLabs #Innovation
-
NEW Mimix™ Geni™ reference standards are out! Developed with Medical Device Innovation Consortium (MDIC) from a Genome-in-a-Bottle cell line and engineered with cancer mutations selected by an expert committee to help improve cancer molecular assay accuracy. Learn more at: http://ms.spr.ly/6046tHgfo #RevvityInnovation #PersonalizedMedicine
-
We’re excited to announce our collaboration with Profluent to launch AI-enhanced base editing via our Pin-point™ platform — setting a new standard for precision and safety in gene editing. Together, we’re empowering researchers to target single nucleotide changes with greater efficiency and fewer off-target effects. This toolbox of therapeutically-relevant base editing systems opens up new possibilities for developing the next generation of cell and gene therapies. http://ms.spr.ly/6049tH5E3
-